<li>abobotulinumtoxina<p>divalproex sodium decreases effects of abobotulinumtoxina by pharmacodynamic antagonism. Minor/Significance Unknown.</p></li><li>acetaminophen<p>divalproex sodium decreases levels of acetaminophen by increasing metabolism. Minor/Significance Unknown. Enhanced metabolism incr levels of hepatotoxic metabolites.</p></li><li>acetaminophen iv<p>divalproex sodium decreases levels of acetaminophen iv by increasing metabolism. Minor/Significance Unknown. Enhanced metabolism incr levels of hepatotoxic metabolites.</p></li><li>acetaminophen rectal<p>divalproex sodium decreases levels of acetaminophen rectal by increasing metabolism. Minor/Significance Unknown. Enhanced metabolism incr levels of hepatotoxic metabolites.</p></li><li>alosetron<p>divalproex sodium will increase the level or effect of alosetron by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.</p></li><li>atracurium<p>divalproex sodium decreases effects of atracurium by pharmacodynamic antagonism. Minor/Significance Unknown.</p></li><li>biotin<p>divalproex sodium decreases levels of biotin by unspecified interaction mechanism. Minor/Significance Unknown. Biotin supplementation may be necessary.</p></li><li>bosentan<p>divalproex sodium will increase the level or effect of bosentan by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.</p></li><li>celecoxib<p>divalproex sodium will increase the level or effect of celecoxib by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.</p></li><li>cisatracurium<p>divalproex sodium decreases effects of cisatracurium by pharmacodynamic antagonism. Minor/Significance Unknown.</p></li><li>clarithromycin<p>clarithromycin increases levels of divalproex sodium by decreasing metabolism. Minor/Significance Unknown.</p></li><li>clonazepam<p>clonazepam, divalproex sodium. Mechanism: unknown. Minor/Significance Unknown. Possible risk of absence seizure.</p></li><li>clozapine<p>divalproex sodium decreases levels of clozapine by plasma protein binding competition. Minor/Significance Unknown.</p></li><li>colestipol<p>colestipol decreases levels of divalproex sodium by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.</p></li><li>cyanocobalamin<p>divalproex sodium decreases levels of cyanocobalamin by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.</p></li><li>dexmethylphenidate<p>dexmethylphenidate increases effects of divalproex sodium by decreasing metabolism. Minor/Significance Unknown.</p></li><li>diclofenac<p>divalproex sodium will increase the level or effect of diclofenac by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.</p></li><li>erythromycin base<p>erythromycin base increases levels of divalproex sodium by decreasing metabolism. Minor/Significance Unknown.</p></li><li>erythromycin ethylsuccinate<p>erythromycin ethylsuccinate increases levels of divalproex sodium by decreasing metabolism. Minor/Significance Unknown.</p></li><li>erythromycin lactobionate<p>erythromycin lactobionate increases levels of divalproex sodium by decreasing metabolism. Minor/Significance Unknown.</p></li><li>erythromycin stearate<p>erythromycin stearate increases levels of divalproex sodium by decreasing metabolism. Minor/Significance Unknown.</p></li><li>ethotoin<p>divalproex sodium, ethotoin. Mechanism: plasma protein binding competition. Minor/Significance Unknown. Valproic acid may increase or decrease phenytoin levels.<span><br><br></span>ethotoin decreases levels of divalproex sodium by increasing metabolism. Minor/Significance Unknown.</p></li><li>ezogabine<p>ezogabine decreases levels of divalproex sodium by Other (see comment). Minor/Significance Unknown. 
Comment: Ezogabine may induce glucuronidation that results in small decreases of trough levels.</p></li><li>felbamate<p>divalproex sodium increases levels of felbamate by decreasing metabolism. Minor/Significance Unknown.</p></li><li>flurbiprofen<p>divalproex sodium will increase the level or effect of flurbiprofen by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.</p></li><li>fluvastatin<p>divalproex sodium will increase the level or effect of fluvastatin by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.</p></li><li>fosphenytoin<p>divalproex sodium, fosphenytoin. Mechanism: plasma protein binding competition. Minor/Significance Unknown. Valproic acid may increase or decrease phenytoin levels.<span><br><br></span>fosphenytoin decreases levels of divalproex sodium by increasing metabolism. Minor/Significance Unknown.</p></li><li>ibuprofen<p>divalproex sodium will increase the level or effect of ibuprofen by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.</p></li><li>incobotulinumtoxina<p>divalproex sodium decreases effects of incobotulinumtoxina by pharmacodynamic antagonism. Minor/Significance Unknown.</p></li><li>isoniazid<p>isoniazid increases levels of divalproex sodium by decreasing metabolism. Minor/Significance Unknown.</p></li><li>levocarnitine<p>divalproex sodium decreases levels of levocarnitine by unspecified interaction mechanism. Minor/Significance Unknown.</p></li><li>mefloquine<p>mefloquine decreases levels of divalproex sodium by unspecified interaction mechanism. Minor/Significance Unknown.</p></li><li>meloxicam<p>divalproex sodium will increase the level or effect of meloxicam by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.</p></li><li>methylphenidate<p>methylphenidate increases effects of divalproex sodium by decreasing metabolism. Minor/Significance Unknown.</p></li><li>onabotulinumtoxina<p>divalproex sodium decreases effects of onabotulinumtoxina by pharmacodynamic antagonism. Minor/Significance Unknown.</p></li><li>pancuronium<p>divalproex sodium decreases effects of pancuronium by pharmacodynamic antagonism. Minor/Significance Unknown.</p></li><li>perampanel<p>perampanel increases levels of divalproex sodium by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>phenobarbital<p>divalproex sodium increases levels of phenobarbital by unspecified interaction mechanism. Minor/Significance Unknown.</p></li><li>phenytoin<p>divalproex sodium, phenytoin. Mechanism: plasma protein binding competition. Minor/Significance Unknown. Valproic acid may increase or decrease phenytoin levels.<span><br><br></span>phenytoin decreases levels of divalproex sodium by increasing metabolism. Minor/Significance Unknown.</p></li><li>piroxicam<p>divalproex sodium will increase the level or effect of piroxicam by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.</p></li><li>primidone<p>divalproex sodium increases effects of primidone by increasing metabolism. Minor/Significance Unknown. Valproic acid enhances the conversion of primidone to phenobarbital.</p></li><li>ramelteon<p>divalproex sodium will increase the level or effect of ramelteon by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.</p></li><li>rapacuronium<p>divalproex sodium decreases effects of rapacuronium by pharmacodynamic antagonism. Minor/Significance Unknown.</p></li><li>rimabotulinumtoxinb<p>divalproex sodium decreases effects of rimabotulinumtoxinb by pharmacodynamic antagonism. Minor/Significance Unknown.</p></li><li>rocuronium<p>divalproex sodium decreases effects of rocuronium by pharmacodynamic antagonism. Minor/Significance Unknown.</p></li><li>ruxolitinib<p>divalproex sodium will increase the level or effect of ruxolitinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>sage<p>sage decreases effects of divalproex sodium by pharmacodynamic antagonism. Minor/Significance Unknown. Theoretical interaction; some species of sage may cause convulsions.</p></li><li>succinylcholine<p>divalproex sodium decreases effects of succinylcholine by pharmacodynamic antagonism. Minor/Significance Unknown.</p></li><li>sulfamethoxazole<p>divalproex sodium will increase the level or effect of sulfamethoxazole by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.</p></li><li>tamoxifen<p>divalproex sodium will increase the level or effect of tamoxifen by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.</p></li><li>tiagabine<p>divalproex sodium decreases levels of tiagabine by increasing metabolism. Minor/Significance Unknown.</p></li><li>tolbutamide<p>divalproex sodium will increase the level or effect of tolbutamide by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.</p></li><li>topiramate<p>topiramate decreases levels of divalproex sodium by increasing metabolism. Minor/Significance Unknown.</p></li><li>tubocurarine<p>divalproex sodium decreases effects of tubocurarine by pharmacodynamic antagonism. Minor/Significance Unknown.</p></li><li>vecuronium<p>divalproex sodium decreases effects of vecuronium by pharmacodynamic antagonism. Minor/Significance Unknown.</p></li><li>voriconazole<p>divalproex sodium will increase the level or effect of voriconazole by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.</p></li>